Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the francophone society of stem cell transplantation and cellular therapy (sfgm-tc) - Université de Lille Accéder directement au contenu
Article Dans Une Revue Bone Marrow Transplantation Année : 2019

Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the francophone society of stem cell transplantation and cellular therapy (sfgm-tc)

Amandine Fayard
  • Fonction : Auteur
Elisabeth Daguenet
  • Fonction : Auteur
Didier Blaise
Patrice Chevallier
  • Fonction : Auteur
Helene Labussiere-Wallet
  • Fonction : Auteur
Ana Berceanu
  • Fonction : Auteur
Gerard Socie
  • Fonction : Auteur
Amandine Charbonnier
  • Fonction : Auteur
Felipe Suarez
  • Fonction : Auteur
Anne Huynh
  • Fonction : Auteur
Melanie Mercier
  • Fonction : Auteur
Claude-Eric Bulabois
  • Fonction : Auteur
Bruno Lioure
  • Fonction : Auteur
Sylvain Chantepie
  • Fonction : Auteur
Yves Beguin
  • Fonction : Auteur
Jean-Henri Bourhis
  • Fonction : Auteur
Jean-Valere Malfuson
  • Fonction : Auteur
Laurence Clement
  • Fonction : Auteur
Regis Peffault de Latour
  • Fonction : Auteur
Jerome Cornillon
  • Fonction : Auteur

Résumé

Several approaches have been developed to overcome historical barriers associated with poor outcomes in the setting of HLA-haploidentical allogeneic transplantation (HaploSCT). Here, we examine the outcome of patients with various hematological disorders undergoing HaploSCT with high-dose, post-transplantation cyclophosphamide. We performed a retrospective study on 381 patients from 30 centers between January 2013 and December 2015. At the last follow-up, a total of 1058 infectious episodes were diagnosed, affecting 90.3% of the cohort. Median time to first infection was 13 days for bacterial, 32 days for viral and 20 days for fungal infections. Around 41% of these infections were of bacterial origin and 35% of viral origin, among which 48.8% of patients presented CMV reactivation. Median of GVHD relapse-free survival, progression-free survival and overall survival were 7.1 months, 19.9 months and 33.5 months, respectively. HSCT procedure was the primary or contributing cause of death (55.6%), followed by relapse of the original disease (34.2%). Infections accounted for 45.7% of the HSCT-related deaths. The present multicenter data on a large cohort of patients receiving HaploSCT with PTCy confirmed the feasibility of the procedure with an acceptable incidence of infectious complications, not different as compared to other haploidentical platforms or HLA-matched transplantation.

Dates et versions

hal-04426945 , version 1 (30-01-2024)

Identifiants

Citer

Amandine Fayard, Elisabeth Daguenet, Didier Blaise, Patrice Chevallier, Helene Labussiere-Wallet, et al.. Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the francophone society of stem cell transplantation and cellular therapy (sfgm-tc). Bone Marrow Transplantation, 2019, Bone Marrow Transplantation, 54, pp.1586-1594. ⟨10.1038/s41409-019-0475-7⟩. ⟨hal-04426945⟩

Collections

RIIP UNIV-LILLE
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More